Alexandria Real Estate Navigates "Very Tough" Market as Life Sciences Demand Stagnates

The largest lab REIT faces a tough operating environment in 2026, with leasing activity nearly halved and occupancy dropping as biotech supply outpaces demand.

By: AXL Media

Published: Apr 30, 2026, 10:29 AM EDT

Source: Bisnow

Leasing Activity and Occupancy Face Steep Declines

The Q1 2026 data highlights the depth of the current market stagnation. Alexandria’s leasing volume was nearly halved quarter-over-quarter, dropping from 1.2 million SF to just 647,000 SF. Occupancy has also taken a hit, falling to 87.7% from 91.7% a year prior. Perhaps most concerning for investors was the total absence of new leases signed with public biotech companies this quarter a tenant segment that typically provides over 25% of the firm's rental income. With over 747,000 SF of leases set to expire in the second quarter alone, the REIT expects continued pressure on occupancy throughout the year.

The Pivot to Advanced Technology

In response to the lab glut, Alexandria is reevaluating 1.6 million SF across five properties, including major redevelopment projects in Cambridge, Massachusetts. The new strategy involves marketing these spaces to "lower-cost alternative uses," such as advanced manufacturing and research, rather than traditional biotech labs. While Marcus noted that rental rates for these uses are less buoyant than lab premiums, the pivot significantly reduces construction costs and provides a path to stabilization for assets that might otherwise sit vacant in a saturated biotech market.

TRANSFORMATIVE ANALYSIS: There is a widening divergence between the financial health of the biotech industry and the health of life science real estate. While venture capital investment remains strong and biotech stock indices (XBI) have hit multi-year highs, the real estate side is suffering from a "supply hangover." Landlords like Alexandria are now competing in a hyper-tenant-friendly market where concessions are high and rents are falling. The "flight to quality" remains, but the sheer volume of new lab space delivered in 2024 and 2025 has effectively capped rental growth for the foreseeable future.

Regulatory and Policy Headwinds